KEY POINTS
- This retrospective single-center analysis from Shenzhen People's Hospital included 100 patients with brain metastases treated between 2017 and 2022, comparing WBRT alone (n=60) with WBRT plus simultaneous integrated boost (SIB; n=40). Primary cancers included lung cancer (52%), breast cancer (29%), and other malignancies (19%); median follow-up was 31 months.
- Standard WBRT delivered 30–40 Gy in 10–20 fractions, while the SIB approach delivered the same whole-brain dose with 36–60 Gy in 10–20 fractions to individual metastatic lesions. Treatment was not randomized: WBRT alone was generally selected for patients with poorer anticipated prognosis or higher extracranial disease burden, whereas SIB was more often selected for patients considered suitable for treatment intensification. Patients with limited metastases suitable for SRS were not represented in this comparison.
- Median overall survival was 11.0 months with WBRT+SIB versus 8.0 months with WBRT alone (p=0.011). One-year overall survival was 51.4% versus 27.3%, two-year survival 35.7% versus 19.4%, and three-year survival 22.3% versus 11.1%, respectively. At analysis, 76 patients had died, including 26 in the SIB group and 50 receiving WBRT alone.
- After adjustment for age, sex, performance status, temozolomide use, intracranial metastatic burden, primary tumor characteristics, and time from initial diagnosis to RT, WBRT+SIB remained associated with lower mortality (adjusted HR 0.51, 95% CI 0.27–0.97; p=0.039). However, the interval from diagnosis to treatment differed significantly between groups (p=0.041), and the documented differences in clinical treatment selection suggest that residual confounding could explain part of the survival association.
- Initial intracranial response rates were numerically higher with SIB but not statistically significant. The reported objective response rates were 57.5% versus 48.3% (p=0.369), and disease control rates were 82.5% versus 76.7% (p=0.443) for WBRT+SIB and WBRT alone, respectively. The response analysis excluded patients without evaluable post-treatment imaging, further limiting confidence in comparative disease-control estimates.
- Reported radiation-induced brain necrosis occurred in 10.0% with WBRT+SIB versus 5.0% with WBRT alone (p=0.439). Grade 3–5 necrosis was reported in 5.0% versus 1.7%, respectively, without a statistically significant difference. Other neurological toxicities, including headache, fatigue and memory impairment, were not significantly different, but the sample was too small and follow-up too limited to establish equivalent safety.
- The study lacked systematic neurocognitive testing, detailed molecular characterization, complete modern systemic therapy information and a randomized comparator. The authors also acknowledge preferential assignment of patients with worse expected survival to WBRT alone, making the observed survival advantage hypothesis-generating rather than evidence that focal boosting independently improves survival or is preferable to SRS in eligible patients.
CLINICAL TAKEAWAY
Adding an integrated boost to WBRT was associated with longer overall survival in this selected retrospective brain metastasis cohort, without a statistically detectable increase in reported neurological toxicity. However, clinically important treatment-selection differences and incomplete neurocognitive assessment prevent routine treatment recommendations based on these results, particularly for patients who are candidates for stereotactic radiosurgery.